重组人血管内皮抑制素联合放化疗治疗宫颈癌研究进展

Research progress on recombinant human endostatin combined with radiotherapy and/or chemotherapy in the treatment of cervical cancer

宫颈癌是全球女性最常见恶性肿瘤之一,局部晚期宫颈癌的治疗以放化疗为主,存在复发率高、生存率低等问题。贝伐珠单抗为一种作用于血管内皮生长因子的血管生成抑制剂,在2013年被美国国立综合癌症网络指南推荐用于复发/转移性晚期宫颈癌的一线治疗。近年来,内皮抑制素等新型血管生成抑制剂靶向药物的研发,进一步优化了局部晚期及晚期宫颈癌患者的靶向治疗新策略。重组人血管内皮抑制素(恩度,endostar)为中国科学家自主研发的一种新型抗血管生成药,虽然已有研究将其应用于宫颈癌治疗,但其是否能成为宫颈癌靶向治疗的新选择,尚需高级别的循证医学证据进一步证实。本文对恩度联合放疗和/或化疗方案的综合治疗模式治疗宫颈癌的临床研究做一综述,为宫颈癌治疗策略的优化提供参考。

Cervical cancer is one of the most common malignant tumors in women worldwide.Locally advanced cervical cancer is mainly treated with radiotherapy and chemotherapy,but there are problems such as high recurrence rate and low survival rate.Bevacizumab,an angiogenic inhibitor that acts on vascular endothelial growth factor(VEGF),has been recommended by the National Comprehensive Cancer Network(NCCN)guidelines for the first-line treatment of recurrent/metastatic advanced cervical cancer in 2013.In recent years,the development of new targeted drugs for angiogenesis inhibitors,such as endostatin,has further optimized the new targeted therapy strategy for patients with locally advanced and advanced cervical cancer.Recombinant human endostatin(endostar)is a novel anti-angiogenesis drug independently developed by Chinese scientists.Although it has been applied in the treatment of cervical cancer,it needs to be further confirmed by high level evidence based medical evidence whether it can become a new option for targeted treatment of cervical cancer.In this article,clinical research progress on the treatment of cervical cancer by endostar combined with radiotherapy and/or chemotherapy was reviewed,aiming to provide reference for the optimization of cervical cancer treatment strategy.